On April 16, 2024, Center specialists joined a meeting of the European Commission, Ukraine, and Moldova on the official screening within negotiating chapter 28 “Consumer and Health Protection.”
At the negotiations in Brussels, the Ukrainian delegation was represented by Deputy Minister of Health for European Integration Maryna Slobodnichenko, heads of structural units of the Ministry of Health of Ukraine, and the National Health Service of Ukraine.
From the Center's side, the meeting was joined online by Deputy Director for Legal Affairs Hanna Husieva, Director of the Department of Expert Evaluation of Preclinical Study and Clinical Trial Materials Taisa Herasymchuk, Director of the Pharmacovigilance Department Tetiana Bashkatova, Acting Director of the Department of Expert Evaluation of Registration Materials Iryna Reshetniak, Director of the Pharmaceutical Activity Department Svitlana Osadchenko, and heads and experts of other structural units.
Our representatives familiarized themselves with the reports presented by the Directorates-General of the European Commission – DG NEAR (Directorate-General for Society and Enlargement Negotiations), DG JUST (Directorate-General for Justice, Freedom and Security), and DG SANTE (Directorate-General for Health and Food Safety). Attention was focused on the main aspects of implementing European legislation for Ukraine and Moldova, which have the status of candidates for membership in the European Union.
During the meeting, the speakers covered topics related to access to medicinal products, health technology assessment, cosmetic products, medical devices, tobacco control, patients’ rights in cross-border health care, regulation of blood, tissues, cells and organs, health information and risk assessment, surveillance and reporting by the European Centre for Disease Prevention and Control, cancer control issues, mental health, rare diseases, health inequalities, healthy lifestyles, prevention of alcohol and drug use, and the EU health program.
Representatives of the Center took an active part in discussing key issues in the regulation of the pharmaceutical sector of healthcare that bring our country closer to full EU membership.
